## HDAC-IN-33

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-145688 2766688-19-9 C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>3</sub> 367.44 HDAC Cell Cycle/DNA Damage; Epigenetics Please store the product under the recommended conditions in the Certificate of Analysis.	NH O H
---	--	--------

BIOLOGICAL ACTIVITY		
BIOLOGICALINOT		
Description	HDAC-IN-33 is a potent HDAC inhibitor with IC <sub>50</sub> s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN- 33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity <sup>[1]</sup> .	
In Vitro	HDAC-IN-33 (Compound 9l) shows good in vivo antitumor efficacies in both HEL xenograft model and murine melanoma model. HDAC-IN-33 promotes the antigen presentation and activate T cells, thereby triggering antitumor immunity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. "Chen C, et al. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity. J Med Chem. 2022 Feb 24;65(4):3667-3683. "

## Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet

